Metabolomics: a promising diagnostic and therapeutic implement for breast cancer
| Autor: | Haoran Li, Zehuan Li, Zhanghan Chen, Ying Jiang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty business.industry Treatment method Cancer Disease medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer Metabolomics 030220 oncology & carcinogenesis Internal medicine medicine Diagnostic biomarker Pharmacology (medical) business Cancer death |
| Zdroj: | OncoTargets and Therapy. 12:6797-6811 |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s215628 |
| Popis: | Breast cancer (BC) is the most commonly diagnosed cancer among women and the leading cause of cancer death. Despite the advent of numerous diagnosis and treatment methods in recent years, this heterogeneous disease still presents great challenges in early diagnosis, curative treatments and prognosis monitoring. Thus, finding promising early diagnostic biomarkers and therapeutic targets and approaches is meaningful. Metabolomics, which focuses on the analysis of metabolites that change during metabolism, can reveal even a subtle abnormal change in an individual. In recent decades, the exploration of cancer-related metabolomics has increased. Metabolites can be promising biomarkers for the screening, response evaluation and prognosis of BC. In this review, we summarized the workflow of metabolomics, described metabolite signatures based on molecular subtype as well as reclassification and then discussed the application of metabolomics in the early diagnosis, monitoring and prognosis of BC to offer new insights for clinicians in breast cancer diagnosis and treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|